Stockscreener 앱 받기
17.50
6.71%
1.10
시간 외 거래:
16.54
-0.96
-5.49%
전일 마감가:
$16.40
열려 있는:
$16.54
하루 거래량:
2,558
Relative Volume:
0.12
시가총액:
$42.84M
수익:
$5.02M
순이익/손실:
$-18.31M
주가수익비율:
-3.8631
EPS:
-4.53
순현금흐름:
$-23.40M
1주 성능:
+1.69%
1개월 성능:
-10.99%
6개월 성능:
+24.11%
1년 성능:
-31.51%
1일 변동 폭
$16.54
$17.50
1주일 범위
$16.40
$17.86
52주 변동 폭
$12.12
$29.19
Vtv Therapeutics Inc Stock (VTVT) Company Profile
명칭
Vtv Therapeutics Inc
전화
336-841-0300
주소
3980 PREMIER DR, HIGH POINT, NC
VTVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
17.50 | 42.84M | 5.02M | -18.31M | -23.40M | -4.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-05-30 | 개시 | H.C. Wainwright | Buy |
| 2018-04-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-08 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 개시 | Northland Capital | Outperform |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2015-09-04 | 개시 | Canaccord Genuity | Buy |
| 2015-08-24 | 개시 | Piper Jaffray | Overweight |
| 2015-08-24 | 개시 | Stifel | Buy |
모두보기
Vtv Therapeutics Inc 주식(VTVT)의 최신 뉴스
vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com - Defense World
(VTVT) Trading Signals - Stock Traders Daily
vTv Therapeutics Inc Reports Q4 2024 EPS of -$0.55, Beating Esti - GuruFocus.com
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewswire
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
VTv Therapeutics: Q4 Earnings Snapshot - CTPost
VTv Therapeutics: Q4 Earnings Snapshot -March 20, 2025 at 06:02 pm EDT - Marketscreener.com
vTv Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FDA Greenlights vTv Diabetes Drug Trial as Cash Reserves Triple to $36.7M - StockTitan
vTv Therapeutics Inc. (VTVT) reports earnings - Quartz
Why Celsius Holdings Stock Popped This Week - The Globe and Mail
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More - Zacks Investment Research
Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Decreases By 13.6% - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Biotech Alert: Searches spiking for these stocks today - TipRanks
StockNews.com Begins Coverage on vTv Therapeutics (NASDAQ:VTVT) - Defense World
vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial - GuruFocus.com
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup - MarketScreener
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Sector Update: Health Care -March 17, 2025 at 03:39 pm EDT - Marketscreener.com
FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
FDA Lifts Clinical Hold, vTv Therapeutics (VTVT) Stock Surges - Stocks Telegraph
vTv Therapeutics up after FDA lifts clinical hold on its oral diabetes treatment study - Seeking Alpha
vTv Therapeutics resumes phase 3 diabetes trial By Investing.com - Investing.com Australia
VTv Therapeutics Says FDA Lifted Clinical Hold On Cadisegliatin Program For Diabetes - Nasdaq
vTv Therapeutics stock surges on FDA update By Investing.com - Investing.com Canada
Vtv Therapeutics Says FDA Lifts Clinical Hold on Cadisegliatin Program for Diabetes; Shares Up Pre-Bell - Marketscreener.com
vTv Therapeutics stock surges on FDA update - Investing.com
vTv Therapeutics resumes phase 3 diabetes trial - Investing.com
vTv Therapeutics Announces Resumption of CATT1 Phase 3 Trial for Cadisegliatin as Potential First Oral Adjunct Therapy for Type 1 Diabetes - Nasdaq
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes - The Manila Times
FDA Green Light: vTv's Revolutionary Oral Diabetes Drug Back on Track with Faster Timeline - StockTitan
3 Quality Compounders on Our Buy List - The Globe and Mail
vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga
vTv Therapeutics Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
vTv Therapeutics (VTVT) Projected to Post Quarterly Earnings on Tuesday - Defense World
Long Term Trading Analysis for (VTVT) - Stock Traders Daily
vTv Therapeutics CFO to Resign in March By Investing.com - Investing.com Canada
vTv Therapeutics CFO to Resign in March - Investing.com
vTv Therapeutics CFO Steven Tuch to Resign - TipRanks
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com - Defense World
(VTVT) Investment Analysis - Stock Traders Daily
Vtv Therapeutics Inc (VTVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):